Ionis Pharmaceuticals
(NASDAQ:IONS)
$40.79
2.03[5.24%]
At close: Nov 30(Delayed 15-Minutes)
Get Real Time Here
$40.79
After Hours: 4:04PM EDT
Day Range38.82 - 40.9252 Wk Range25.04 - 48.82Open / Close38.94 / 40.79Float / Outstanding120M / 142.1M
Vol / Avg.1.6M / 1MMkt Cap5.8BP/E553.7150d Avg. Price44.02
Div / Yield-Payout Ratio-Total Float120MEPS-0.33

Ionis Pharmaceuticals Stock (NASDAQ:IONS), Quotes and News Summary

Ionis Pharmaceuticals Stock (NASDAQ: IONS) stock price, news, charts, stock research, profile.

Loading...
Day Range38.82 - 40.9252 Wk Range25.04 - 48.82Open / Close38.94 / 40.79Float / Outstanding120M / 142.1M
Vol / Avg.1.6M / 1MMkt Cap5.8BP/E553.7150d Avg. Price44.02
Div / Yield-Payout Ratio-Total Float120MEPS-0.33
PRNewswire - Nov 10, 2022, 7:05AM
PRNewswire - Nov 9, 2022, 7:00AM
PRNewswire - Aug 30, 2022, 7:05AM
Seeking Alpha - Nov 9, 2022, 11:52AM
Seeking Alpha - Nov 8, 2022, 12:37PM
Seeking Alpha - Oct 19, 2022, 3:19AM
InvestorPlace - Sep 29, 2022, 3:59PM
Seeking Alpha - Aug 17, 2022, 1:49PM
Sector: Health Care.Industry: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-23
REV
Q3 2022Est.ActualSurprise
EPS-0.740-0.160 0.5800
REV143.840M160.000M16.160M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Ionis Pharmaceuticals (IONS) stock?

A

You can purchase shares of Ionis Pharmaceuticals (NASDAQ: IONS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Ionis Pharmaceuticals's (IONS) competitors?

Q

What is the target price for Ionis Pharmaceuticals (IONS) stock?

A

The latest price target for Ionis Pharmaceuticals (NASDAQ: IONS) was reported by Morgan Stanley on Thursday, November 10, 2022. The analyst firm set a price target for 56.00 expecting IONS to rise to within 12 months (a possible 37.29% upside). 18 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Ionis Pharmaceuticals (IONS)?

A

The stock price for Ionis Pharmaceuticals (NASDAQ: IONS) is $40.79 last updated Today at November 30, 2022, 9:00 PM UTC.

Q

Does Ionis Pharmaceuticals (IONS) pay a dividend?

A

There are no upcoming dividends for Ionis Pharmaceuticals.

Q

When is Ionis Pharmaceuticals (NASDAQ:IONS) reporting earnings?

A

Ionis Pharmaceuticals’s Q4 earnings are confirmed for Thursday, February 23, 2023.

Q

Is Ionis Pharmaceuticals (IONS) going to split?

A

There is no upcoming split for Ionis Pharmaceuticals.

Q

What sector and industry does Ionis Pharmaceuticals (IONS) operate in?

A

Ionis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.